Translating the concept of suppressor/regulatory T cells to clinical applications

International Reviews of Immunology

Volumn 25, Issue 1-2, 2006, Pages 27-47

  Franco, Alessandra ^a   Albani, Salvatore ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b IACOPO Institute for Translational Medicine   (United States)

^c Androclus Therapeutics Inc   (United States)

Author keywords

Immunoregulation; Immunotherapy; Tregs

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEUROPILIN 1;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; AUTOIMMUNITY; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DENDRITIC CELL; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TRANSPLANTATION;

ANTIGENS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; LIGANDS; MAJOR HISTOCOMPATIBILITY COMPLEX; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION TOLERANCE;

EID: 33644968930     PISSN: 08830185     EISSN: None     Source Type: Journal    
DOI: 10.1080/08830180500544506     Document Type: Review

References (163)

1. K.C. Garcia, M. Degano, R.L. Stanfield, A. Brunmark, M.R. Jackson, P.A. Peterson, L. Teyton, and I.A. Wilson, An alpha/beta T cell receptor structure at 2.5 A and its orientation in the TcR-MHC complex, Science, 274: 209-219, 1996.
2. B.P. Babbitt, P.M. Allen, G. Matsueda, E. Haber, and E.R. Unanue, Binding of immunogenic peptides to Ia histocompatibility molecules, Nature, 317: 359-361, 1985.
3. S. Buus, A. Sette, S.M. Colon, D.M. Jenis, and H.M. Grey, Isolation and characterization of antigen-Ia complexes involved in T cell recognition, Cell, 47: 1071, 1986.
4. T.N. Schumacher, M.T. Heemels, J.J. Neefjes, W.M. Kast, C.J. Melief, and H.L. Ploegh, Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro, Cell, 62: 563-567, 1990.
5. P.J. Bjorkman, M.A. Saper, B. Samraoui, W.S. Bennett, J.L. Strominger, and D.C. Wiley, The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens, Nature, 329: 512-518, 1987.
6. D.H. Fremont, M. Matsumura, E.A. Stura, P.A. Peterson, and I.A. Wilson, Crystal structure of two viral peptides complex with murine class I H-2Kb, Nature, 257: 919-927, 1992.
7. A.W. Goldrath and M.J. Bevan, Selecting and maintaining a divesre T cell repertoire, Nature, 402: 255-262, 1999.
8. R.N. Germain and I. Stefanova, The dynamics of T cell receptor signaling: Complex orchestration and the key role of tempo and cooperation, Annu. Rev. Immunol., 17: 467-522, 1999.
9. C.A.J. Janeway, Ligands for the T cell receptor: Hard time for avidity models, Immunol. Today, 16: 223-225, 1995.
10. H.Y. Ding, B.M. Baker, D.N. Garboczi, W.E. Biddison, and D.C. Whiley, Four A6-TcR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical, Immunity, 11: 45-56, 1999.
11. P.A. van der Merwe, S.J. Davis, A.S. Shaw, and M.L. Dustin, Cytoskeletal polarization and redistribution of cell-surface molecules during T cell antigen recognition, Semin. Immunol., 12: 5-21, 1997.
12. A.S. Shaw and M.L. Dustin, Making the T cell receptor go the distance: A topological view of T cell activation, Immunity, 6: 361-369, 1997.
13. S.J. Davis and P.A. van der Merwe, The structure and ligan interactions of CD2: implication for T cell function, Immunol. Today, 17: 177-187, 1996.
14. A. Sette, J. Alexander, J. Ruppert, K. Snoke, A. Franco, G. Ishioka, and H.M. Grey, Antigen analogs MHC complexes as specific T cell receptor antagonists, Ann. Rev. Immunol., 12: 413-431, 1994.
15. M.F. Bachmann and P.S. Ohashi, The role of T-cell receptor dimerization in T cell activation, Immunol. Today, 20: 568-576, 1999.
16. J.H. Brown, T.S. Jardetzky, J.C. Gorga, L.J. Stern, R.G. Uran, J.L. Strominger, and D.C. Wiley, Three dimensional structure of the human class II histocompatibility antigen HLA-DR1, Nature, 364: 33-39, 1993.
17. F. Giannoni, J. Barnett, K. Bi, R. Samodal, P. Lanza, P. Marchese, R. Billetta, R. Vita, M.R. Klein, B. Prakken, W.W. Kwok, E. Sercaz, A. Altman, and S. Albani, Clustering of T cell ligands on artificial APC membranes influences T cell activation and protein kinase C Theta translocation to the T cell plasma membrane, J. Immunol., 176: 3204-3211, 2005.
18. S. Valitutti, S. Muller, M. Dessing, and A. Lanzavecchia, Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy, J. Exp. Med., 183: 1917-1921, 1996.
19. C. Rosette, G. Werlen, M.A. Daniels, P.O. Holman, S.M. Alam, P.J. Travers, N.R.J. Gascoigne, E. Palmer, and S.C. Jameson, The impact od duration versus extent of TcR occupancy on T cell activation: a revision of the kinetic proofreading model, Immunity, 15: 59-70, 2001.
20. S. Hugues, L. Fetler, L. Bonifaz, J. Helft, F. Amblard, and S. Amigorena, Distinct T cell dynamics in lymph nodes during the induction of tolerance immunity, Nat. Immunol., 5: 1201-1202, 2004.
21. C.V. Harding and E.R. Unanue, Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation, Nature, 346: 574-576, 1990.
22. S. Demotz, H.M. Grey, and A. Sette, The minimal number of class II MHC-antigen complexes needed for T cell activation, Science, 249: 1028-1030, 1990.
23. A. Grakoui, S.K. Bromley, C. Sumen, M.M. Davis, A.S. Shaw, P.M. Allen, and M.L. Dustin, The immunological synapse: a molecular machine controlling T cell activation, Science, 285: 221-227, 1999.
24. S. Valitutti, S. Muller, M. Cella, E. Padovan, and A. Lanzavecchia, Serial triggering of many T-cell receptors by a few peptide-MHC complexes, Nature, 375: 148-151, 1995.
25. A. Lanzavecchia, G. Iezzi, and A. Viola, From TCR engagement to T cell activation: A kinetic view of T cell behaviour, Cell, 96: 1-4, 1999.
26. A. Lanzavecchia and F. Sallusto, Antigen decoding by T lymphocytes: From synapses to fate determination, Nat. Immunol., 2: 487-492, 2001.
27. P. Matzinger, Tolerance, danger and the extended family, Annu. Rev. Immunol., 12: 991-1045, 1994.
28. H. Jiang and L. Chess, An integrated view of suppressor T cell subsets in immunoregulation, J. Clin. Invest., 114: 1198-1208, 2004.
29. S. Paust and H. Cantor, Regulatory T cells and autoimmune diseases, Immunol. Rev., 204: 195-207, 2005.
30. R.K. Gershon and K. Kondo, Cell interactions in the induction of tolerance: The role of thymic lymphocytes, Immunology, 18: 723-737, 1970.
31. H. Cantor and E.A. Boyse, Functional subclasses of T lymphocytes bearing different Ly antigens. II. Cooperation between subclasses of Ly+ cells in the geneation of killer activity, J. Exp. Med., 141: 1390-1399, 1975.
32. H. Cantor and R.K. Gerhon, Immunological circuits: Cellular composition, Fed. Proc., 38: 2058-2064, 1979.
33. D.D. Eardley and R.H. Gershon, Feedback induction of suppressor T cell activity, J. Exp. Med., 142: 524-529, 1975.
34. H. Kimura and D.B. Wilson, Anti-idiotypic cytotoxic T cells in rats with graft-versus-host disease, Nature, 308: 463-464, 1984.
35. D. Sun, Y. Qin, J. Chluba, J.T. Epplen, and H. Wekerle, Suppression of experimentally induced autoimmune encephalomyelitis by cytolytic T-T interactions, Nature, 332: 843-845, 1988.
36. H. Jiang, S.I. Zhang, and B. Pernis, Role of CD8+ T cells in murine experimental allergic encepaholomyelitis, Science, 256: 1213-1215, 1992.
37. D. Koh, et al., Less mortality but more relapses in experimental allergic encephalomyelitis in CD8-/- mice, Science, 256: 1210-1213, 1992.
38. H. Jiang, et al., Murine CD8+ T cells that specifically delete autologous CD4+ T cells expressing V beta 8 TcR: A role for the Qa-1 molecule, Immunity, 2: 185-194, 1995.
39. H. Jiang, et al., Regulatory CD8+ T cells fine-tune the myelin basic protein reactive T cell receptor V beta repertoire during experimental autoimmune encephalomyelitis, Proc. Natl. Acad. Sci. USA, 100: 8378-8383, 2003.
40. T.H. Stanton, C.E. Calkins, J. Jandinski, D.J. Schendel, O. Stutman, and H. Cantor, The Qa-1 antigenic system. Relation of Qa-1 phenotypes to lymphocytes sets, mitogen responses, and immune functions, J. Exp. Med., 148: 963-973, 1978.
41. H. Cantor, J. Hugenberger, L. McVay-Boudreau, D.D. Eardly, J. Kemp, F.W. Shen, and R.K. Gershon, Immunoregulatory circuits among T-cell sets. Identification of a subpopulation of T-helper cells that induces feedback inhibition, J. Exp. Med., 148: 963-973, 1978.
42. D. Hu, K. Ikizawa, L. Lu, M.E. Sanchirico, M.L. Shinoara, and H. Cantor, Analysis of regulatory CD8+ T cells in Qa-1-deficient mice, Nat. Immunol., 5: 516-523, 2004.
43. H. Jiang and L. Chess, The specific regulation of immune responses by CD8+ T cells restricted by the MHC class Ib molecule, Qa-1, Annu. Rev. Immunol., 18: 185-216, 2000.
44. V. Panautsakopoulou, K.M. Huster, N. McCarty, E. Feinberg, R. Wang, K.W. Wucherpfenning, and H. Cantor, Suppression of autoimmune disease after vaccination with autoreactive T cells that express Qa-1 peptide complexes, J. Clin. Invest., 113: 1218-1224, 2004.
45. R.S. McHughs, et al., Immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor, Immunity, 2002: 1174-1182, 2002.
46. J. Shimuzu, S. Yamazaki, T. Takahashi, Y. Ishida, and S. Sakaguchi, Stimulation of CD25+ CD4+ regulatory T cells through GITR breaks immunological self-tolerance, Nat. Immunol., 3: 132-142, 2002.
47. L.A. Stephens and D. Mason, CD25 is a marker for CD4+ thymocytes that prevent autoimmune diabetis in rats, but peripheral T cells with this function are found in both CD25+ and CD25- subpopulations, J. Immunol., 165: 3105-3110, 2005.
48. S.J. Bensinger, A. Bandeira, M.S. Jordan, A.J. Canton, and T.M. Laufer, Major histocompatibility complex class II-positive cortical epithelium mediates the selection of CD4+ CD25+ immunoregulatory T cells, J. Exp. Med., 194: 427-438, 2001.
49. J.D. Fontenot, M.A. Gavin, and A.Y. Rudensky, Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells, Nat. Immunol., 4: 330-336, 2003.
50. S. Hori, T. Nomura, and S. Sakaguchi, Control of regulatory T cell development by the transcription factor Foxp3, Science, 299: 1057-1061, 2003.
51. D. Bruder, et al., Neropilin-1: A surface marker of regulatory T cells, Eur. J. Immunol., 34: 623-630, 2004.
52. I. Apostolou, A. Sarukhan, L. Klein, and H. von Boehmer, Origin of regulatory T cells with known specificity for antigens, Nat. Immunol., 3: 756-763, 2002.
53. I. Apostolou and H. von Boemer, In vivo instruction od suppressor committment in naive T cells, J. Exp. Med., 199: 1401-1408, 2004.
54. G.C. Furtado, D. Olivares-Villagomez, M.A. Curotto de Lafaille, A.K. Wensky, J.A. Latkowski, and J.J. Lafaille, Regulatory T cells in spontaneous autoimmune encephalomyelitis, Immunol. Rev., 182: 122-134, 2001.
55. A. Gonzales, I. Andre-Schmutz, C. Carnaud, D. Mathis, and C. Benoist, Damage control, rather than unresonsiveness, effected by protective DX5+ T cells in autoimmune diabetes, Nat. Immunol., 2001: 1117-1125.
56. M.A. Curotto de Lafaille and J.J. Lafaille, CD4+ regulatory T cells in autoimmunity and allergy, Curr. Opin. Immunol., 14: 771-778, 2002.
57. K. Kretschmer, I. Apostolou, D. Hawiger, K. Khazaie, M. Nussenzweig, and H. von Boehmer, Inducing and expanding regulatory T cell populations by foreign antigen, Nat. Immunol., 6: 1-9, 2005.
58. J.D. Fontenot, J.P. Rasmussen, M.A. Gavin, and A.Y. Rudensky, A function for interleukin 2 in Foxp3-expressing regulatory T cells, Nat. Immunol., 6: 1142-1151, 2005.
59. P. Paharam, C.E. Lomen, D.A. Lawlor, J.P. Ways, N. Holmes, H.L. Coppin, R.D. Salter, A.M. Wan, and P.D. Ennis, Nature of polymorphism in HLA-A-B and -C molecules, Proc. Natl. Acad. Sci., 85: 4005-4009, 1988.
60. K. Falk, O. Rotzschke, Stevanovi, G. Jung, and H.-G. Rammensee, Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules, Nature, 351: 290-296, 1991.
61. M. Matsumura, D.H. Fremont, P.A. Peterson, and I.A. Wilson, Emerging principles for the recognition of peptides antigens by MHC class I molecules, Science, 257: 927-934, 1992.
62. W.D. Madden DR, Peptide binding to the major histocompatibility complex molecules, Curr. Opin. Struct. Biol., 2: 300-304, 1992.
63. W. Zhang, A.C. Young, M. Imarai, S.G. Nathenson, and J.C. Sacchettini, Crystal structure of the major histocompatibility complex class I H-2Kb molecule containing a single viral peptide: implications for peptide binding and T-cell receptor recognition, Proc. Natl. Acad. Sci. USA, 89: 8403-8407, 1992.
64. H.C. Guo, T.S. Jardetzky, T.P. Garrett, W.S. Lane, J.L. Strominger, and D.C. Wiley, Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle, Nature, 360: 364-366, 1992.
65. D.R. Madden, D.N. Garbogzi, and D.C. Wiley, The antigenic identify of peptide-MHC complexes: A comparison of the conformation of five viral peptides presented by HLA A2, Cell, 75: 693-708, 1993.
66. M.A. Saper, P.J. Bjorkman, and D.C. Wiley. Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 A resolution, J. Mol. Biol., 219: 277-319, 1991.
67. A. Sette, S. Buus, S. Colon, J.A. Smith, C. Miles, and H.M. Grey, Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells, Nature, 328: 395-399, 1987.
68. J. Sloan-Lancaster, A.S. Shaw, J.B. Rothbard, and P.M. Allen, Partial T cell signaling: altered phospho-zeta and lack of Zap 70 recruitment in APL-induced T cell energy, Cell, 79: 913-922, 1994.
69. J. Madrenas, R.L. Wange, J.L. Wang, N. Isakov, L.E. Samelson, and R.N. Germain, Z phosphorylation without Zap 70 activation induced by TcR antagonist and partial agonist, Science, 267: 515-518, 1995.
70. M.T. De Magistris, J. Alexander, M. Coggeshal, A. Altman, F.C.A. Gaeta, H.M. Grey, and A. Sette, Analog/antigen/MHC complexes act as antagonist of the T cell receptor, Cell, 68: 625-634, 1992.
71. B.D. Evavold and P.M. Allen, Separation of IL4 production fronm Th cell proliferation and lymphokine production using peptide analogs, Science, 252: 1308-1310, 1991.
72. S.C. Jameson and M.J. Bevan, T cell receptor antagonists and partial agonists, Immunity, 2: 1-11, 1995.
73. J. Sloan-Lancaster, B.D. Evavold, and P.M. Allen, Induction of T cell anergy by altrered T cell receptor ligand on live antigen presenting cells, Nature, 363: 156-159, 1993.
74. A. Franco, S. Southwood, T. Arrhenius, V.J. Kuchroo, H.M. Grey, A. Sette, and G.Y. Ishioka, T cell receptor antagonist peptides are highly effective inhibitors of experimental allergic encephalomyelitis, Eur. J. Immunol., 24: 940, 1994.
75. V.K. Kuchroo, G.M. Greer, D. Kaul, G. Ishioka, A. Franco, A. Sette, R.A. Sobel, and M.B. Less, A single TcR antagonist peptide inhibits experimental allergic encephalomyelitis by a diverse T cell repertoire, J. Immunol., 153: 3326-3336, 1994.
76. L.B. Nicholson, J.M. Greer, R.A. Sobel, M.B. Lees, and V.K. Kuchroo, An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis, Immunity, 3: 397-405, 1995.
77. A. Gaur, S.A. Boehme, D. Chalmers, P.D. Crowe, A. Pahuja, N. Ling, S. Brocke, L. Steinman, and P.J. Conlon, Amelioration of relapsing experimental autoimmune encephalomyelitis with altered myelin basic protein peptides involves different cellular mechanisms, J. Neuroimmunol., 74: 149-158, 1997.
78. S.M. Anderton, S. Kissler, A.G. Lamont, and B.C. Wraith, Therapeutic potential of TCR antagonists is determined by their ability to modulate a diverse repertoire of autoreactive T cells, Eur. J. Immunol., 29: 1850-1857, 1999.
79. D.A. Young, L.D. Lowe, S.S. Booth, M.J. Whitters, L. Nicholson, V.K. Kuchroo, and M. Collins, IL-4, IL-10, IL-13, and TGF-beta from an altered peptide ligand-specific Th2 cell clone down-regulate adoptive transfer of experimental autoimmune encephalomyelitis, J. Immunol., 164: 3563-3572, 2000.
80. F.R. Fischer, L. Santambrogio, Y. Luo, M.A. Berman, W.W. Hancock, and M.E. Dorf, Modulation of experimental autoimmune encephalomyelitis: Effect of altered peptide ligand on chemokine and chemokine receptor expression, J. Neuroimmunol., 110: 195-208, 2000.
81. N. Heijmans, P.A. Smith, M.M. Morris-Downes, G. Pryce, D. Baker, A.V. Donaldson, B. Hart, and S. Amor, Encephalitogenic and tolerogenic potential of altered peptide ligands of MOG and PLP in Biozzi ABH mice, J. Neuroimmunol., 167: 23-33, 2005.
82. A. Lanzavecchia and F. Sallusto, Understanding the generation and function of memory T cell subsets. Curr. Opin. Immunol., 16: 82-89, 2005.
83. R.M. Steinman, The dendritic cell system and its role in immunogenicity, Annu. Rev. Immunol., 9: 271-296, 1991.
84. J. Banchereau, F. Briere, C. Caux, J. Davoust, S. Lebecque, Y.-J. Liu, B. Pulendran, and K. Palucka, Immunobiology of dendritic cells, Annu. Rev. Immunol., 18: 767-811, 2000.
85. A. Lanzavecchia and F. Sallusto, Regulation of T cell immunity by dendritic cells, Cell, 106: 263-266, 2001.
86. J.P. Ridge, E.J. Fuchs, and P. Matzinger, Neonatal tolerance revisited: Turning on newborn T cells with dendritic cells, Science, 271: 1723-1726, 1996.
87. A.E. Morelli, Dendritic cells: regulators of alloimmunity and opportunity for tolerance induction, Immunol. Rev., 196: 125-146, 2003.
88. M.K. Jenkins, The ups and downs of T cell costimulation, Immunity, 443-446, 1994.
89. R.M. Steinman, D. Hawiger, and M.C. Nussenzweig, Tolerogenic dendritic cells, Annu. Rev. Immunol., 21: 685-711, 2003.
90. S.K. Yoshinaga, J.S. Whoriskey, S.D. Khare, U. Sarmiento, G. Guo, T. Horan, G. Shih, M. Zhang, M.A. Coccia, T. Kohno, A. Tafuri-Bladt, D. Brankow, P. Campbell, D. Chang, L. Chiu, J. Dai, G. Duncan, G.S. Elliott, A. Hui, A., S.M. McCabe, S. Scully, A. Shainian, C.L. Shaklee, G. Van, T.M. Mak, and G. Senaldi, T-cell co-stimulation through B7RP-1 and ICOS, Nature, 402: 827-832, 1999.
91. A. Hutloff, A.M. Dittrich, K.C. Beier, B. Eljaschewitsch, R. Kraft, I. Agnagnostopulos, and R.A. Kroczek, ICOS is an inducibile T cell co-stimulator structurally and functionally related to CD28, Nature, 397: 263-266, 1999.
92. A. Tafuri, A. Shahinian, F. Bladt, S.K. Yoshinaga, M. Jordana, A. Wakeham, L.M. Boucher, D. Bouchard, V.S.F. Chan, G. Duncan, B. Odermatt, A. Ho, A. Itie, T. Horan, J.S. Whoriskey, T. Pawson, J.M. Penninger, P. Ohashi, and T.M. Mack, ICOS is essential for effective T-helper-cell responses, Nature, 409: 105-109, 2001.
93. S.K. Yoshinaga, M. Zhang, J. Pistillo, T. Horan, S.D. Khare, K. Miner, M. Sonnemberg, T. Boone, D. Brankow, T. Dai, J. Delaney, H. Han, A. Hui, T. Kohno, R. Manoukian, J.S. Whoriskey, and M.A. Coccia, Characterization of a new human B7-related protein: B7RP-1 the ligand to the co-stimulatory protein ICOS, Int. Immunol., 12: 1439-1447, 2000.
94. M.E. Keir and A.H. Sharpe, The B7/CD28 costimulatory family in autoimmunity, Immunol. Rev., 204: 128-143, 2005.
95. L. Tuosto and O. Acuto, CD28 affects the earliest signaling events generated by TCR engagement, Eur. J. Immunol., 28: 2131-2142, 1998.
96. U. Grohmann, et al., CTL-4-Ig regulates tryptophan catabolism in vivo, Nat. Immunol., 3: 1097-1101, 2002.
97. U. Grohmann, et al., A defect in tryptophan catabolism impairs tolerance in non-obese diabetic mice, Nat. Immunol., 198: 153-160, 2003.
98. F. Fallarino, et al., Modulation of tryptophane metabolism by regulatory T cells, Nat. Immunol., 4: 1206-1212, 2003.
99. P.H. Tan, J.B. Yates, S.A. Xue, C. Chan, W.J. Jordan, J.E. Harper, M.P. Watson, R. Dong, M.A. Ritter, R.I. Lechler, G. Lombardi, and A.J. George, Creation of tolerogenic human DC via intracellular CTLA4: A novel strategy with potential in clinical immunosuppression, Blood, 106: 2936, 2005.
100. G. Vlad, R. Cortesini, and N. Suciu-Foca, Licence to heal: Bidirectional interaction of antigen-specific regulatory T cells and tolerogenic APC, J. Immunol., 174: 5907-5914, 2005.
101. A. Mimran, F. Mor, F.J. Quintana, and I.R. Cohen, Anti-ergotypic T cells in naive rats, J. Autoimmun., 24: 191-201, 2005.
102. I.R. Cohen, F. Quintana, and A. Mimran, Tregs in T cell vaccination: Exploring the regulation of the regulation, J. Clin. Invest., 114: 1227-1232, 2004.
103. R.J. Greenwald, G.J. Freeman, and A.H. Sharpe, The B7 family revisited, Annu. Rev. Immunol., 23: 515-548, 2005.
104. R.M. Locksley, N. Killeen, and M.J. Lenardo, The TNF and TNF receptor super-families: Integrating mammalian biology, Cell, 104: 487-501, 2001.
105. S.P. Shoenberger, R.E.M. Toes, E.I.H. van der Voort, R. Offringa, and C.J.M. Melief, T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interaction, Nature, 393: 480-483, 1998.
106. S.R. Bennett, F.R. Carbone, F. Karamalis, R.A. Flavell, J.F.P. Miller, and W.R. Heath, Help for cytotoxic T cells responses is mediated by CD40, Nature, 480: 393-483, 1998.
107. J.P. Ridge, F. Di Rosa, and P. Matzinger, A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T killer cell, Nature, 393: 474-477, 1998.
108. T.H. Watts, TNF/TNFR family members in costimulation of T cell responses, Annu. Rev. Immunol., 23: 23-68, 2005.
109. B. Salomon and J.A. Bluestone, Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation, Annu. Rev. Immunol., 19: 225-252, 2001.
110. A.A. Itano and M.K. Jenkins, Antigen presentation to naive CD4 T cells in the lymph node, Nat. Immunol., 4: 733-739, 2003.
111. P. Martin, G.M. Del Hoyo, F. Anjuere, C.V. Arias, H.H. Vargas, L.A. Fernandez V. Parrillas, and C. Ardavin, Characterization of a new subpopulation of mouse CD8alpha+ B220+ dendritic cells endowed with type 1 interferon production capacity and tolerogenic potentials, Blood, 100: 390-393, 2002.
112. L. Adorini, Immunotherapeutic approaches in multiple sclerosis, J. Neurol. Sci., 223: 13-24, 2004.
113. M. Colonna, H. Nakajima, and M. Cella, A family of inhibitory and activating Ig-like receptors that modulate function of lymphoid and myeloid cells, Semin. Immunol., 12: 121-127, 1999.
114. J.V. Ravatech and L.L. Lanier, Immune inhibitory receptors, Science, 290: 84-89, 2000.
115. C.C. Chang, R. Ciubotariu, J.S. Manavalan, et al., Tolerization of dendritic cells by Ts cells: The crucial role of inhibitory receptors ILT3 and ILT4, Nat. Immunol., 3: 237-243, 2002.
116. J. Li, Z. Liu, Z. Jiang, R. Cortesini, S. Lederman, and N. Suciu-Foca, T suppressor lymphocytes inhibit NF-kB-mediated transcription of CD86 gene in APC, J. Immunol., 163: 6386-6392, 1999.
117. D. Brown, J. Trowsdale, and R. Allen, The LILR family: Modulation of innate and adaptive immune pathways in health and disease, Tissue Antigens, 64: 215-225, 2004.
118. H. Hackstein and A.W. Thomson, Dendritic cells: Emerging pharmacological targets of immunosuppressive drugs, Nat. Rev. Immunol., 4: 24-34, 2004.
119. L. Adorini, G. Penna, N. Giarratana, and M. Uskokovic, Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases, J. Cell. Biochem., 88: 227-233, 2003.
120. P.S. Piraino, T.A. Yednock, S.B. Freedman, E.K. Messersmith, M.A. Pleiss, and S.J. Karlik, Suppression of acute experimental allergic encephalomyelitis with a small molecule inhibitor of alpha4 integrin, Mult. Scler., 11: 683-690, 2005.
121. P.S. Piraino, T.A. Yednock, E.K. Messersmith, M.A. Pleiss, S.B. Freedman, R.R. Hammond, and S.J. Karlik, Prolonged reversal of chronic experimental allergic encephalomyelitis using a small molecule inhibitor of alpha4 integrin, Neuroimmunology, 131: 147-159, 2002.
122. L. Bertry-Coussot, B. Lucas, C. Danel, L. Halbwachs-Mecarelli, J.F. Bach, L. Chatenoud, and P. Lemarchand, Long-term reversal of established autoimmunity upon transient blockade of the LFA-1/intercellular adhesion molecule-1 pathway, J. Immunol. 168: 3641-3648, 2002.
123. T.A. Yednock, C. Cannon, L.C. Fritz, F. Sanchez-Madrid, L. Steinman, and N. Karin, Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin, Nature, 356: 63-66, 1992.
124. A.P. Cope and G. Sonderstrup, Evaluating candidate autoantigens in rheumatoid arthritis, Springer Semin. Immunopathol., 20: 23-39, 1998.
125. V.M. Corrigal, M.D. Bodman-Smith, M.S. Fife, B. Canas, L.K. Myers, P. Wooley, et al., The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis, J. Immunol., 166: 1492-1498, 2001.
126. B. Prakken, W. Kuis, W. Van Eden, and S. Albani, Heatshock proteins in juvenile idiopathic arthritis: Keys for understanding remitting arthritis and candidate antigens for immunotherapy, Curr. Rheumatol. Rep., 4: 466-473, 2002.
127. V. Van Eden, Z.R. van Der, and B. Prakken, Heat-shock proteins induce T cell regulation of chronic inflammation, Nat. Rev. Immunol., 5: 318-330, 2005.
128. S. Albani, E.C. Keystone, J.L. Nelson, W.E.R. Ollier, A. La Cava, A.C. Montemayor, et al., Positive selection in autoimmunity: Abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis, Nat. Med., 1: 448-152, 1995.
129. S. Albani, A. Ravelli, M. Massa, F. De Benedetti, G. Andree, J. Roudier, et al., Immune responses to the Escherichia coli dnaJ heat shock protein in juvenile rheumatoid arthritis and their correlation with disease activity, J. Pediatr., 124: 561-565, 1994.
130. S. Albani and D.A. Carson, A multistep molecular mimicry hypothesis for the pathogenesis of rheumatoid arthritis, Immunol. Today, 17: 466-470, 1996.
131. A.B.J. Prakken, W. van Eden, G.T. Rijkers, W. Kuis, E.A. Toebes, E.R. de Graeff-Meeder, et al., Autoreactivity to human heat-shock protein 60 predicts isease remission in oligoarticular juvenile rheumatoid arthritis, Arthritis Rheum., 39: 1826-1832, 1996.
132. E.R. de Graeff-Meeder, W. Van Eden, G.T. Rijkers, A.B.J. Prakken, W. Kuis, M.W. Voorhost-Ogink, et al., Juvenile chronic arthritis: T cell reactivity to Human HSP60 in patients with favourable course of arthritis, J. Clin. Invest., 95: 934-940, 1995.
133. A.G. Pockley, Heat shock proteins as regulators of the immune response, Lancet, 362: 469-476, 2003.
134. A.P. Cope, S.D. Patel, F. Hall, M. Congia, H.A. Hubers, G.F. Verheijden, et al., T cell responses to a human cartilage autoantingen in the context of rheumatoid arthritis-associated and non associated HLA-DR4 alleles, Arthritis Rheum., 42: 1497-1507, 1999.
135. G.A. Rook, G. Ristori, M. Salvetti, G. Giovannoni, E.J. Thomson, and J.L. Stanford, Bacterial vaccines for the treatment of multiple sclerosis and other autoimmune disorders, Immunol. Today, 21: 503-508, 2000.
136. L. Steinman, Myelin-specific CD8+ T cells in multiple sclerosis, J. Exp. Med., 194: F27-F30, 2001.
137. B.J. Prakken, R. Samodal, T.D. Le, F. Giannoni, G. Puga Yung, J. Scavulli, D. Amox, S. Roord, I. de Kleer, D. Bonnin, P. Lanza, C. Berry, M. Massa, R. Billetta, and S. Albani, Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis, Proc. Natl. Acad. Sci. USA, 101: 4228-4233, 2004.
138. A. La Cava, J.L. Nelson, W.E.R. Ollier, A. MacGregor, E.C. Keystone, and J.C. Thorne, Genetic bias in immune responses to a cassette shared by different microorganisms in patients with rheumatoid arthritis, J. Clin. Invest., 100: 658-663, 1997.
139. A. Holz, B. Bielekova, R. Martin, and M.B. Oldstone, Myelin-associated oligodendrocytic basic protein: Identification of an encephalitogenic epitope and association with multiple sclerosis, J. Immunol., 164: 1103-1109, 2000.
140. B. Bielekova, P.A. Muraro, L. Golestaneh, J. Pascal, H.F. McFarland, and R. Martin, Preferential expansion of autoreactive T lymphocytes from the memory T-cell pool by IL-7, J. Neuroimmunology, 100: 115-123, 1999.
141. M. Massa, R. Campanelli, A. Uccelli, V. Meli, P. Lanza, R. Billetta, et al., Identification of novel lead compounds in modulation of pathogenic immune responses in multiple sclerosis, [Abstract]. International Conference on Autoimmunity, Budapest, 2004.
142. I.M. de Kleer, S.M. Kamphuis, G.T. Rijekers, L. Scholtens, G. Gordon, W. de Jager, et al., The spontaneous remission of juvenile idiopathic arthritis is characterized by CD30+ T cells directed to human heat-shock protein 60 capable of producing the regulatory cytokine interleukin-10, Arthritis Rheum., 48: 2001-2010, 2003.
143. S. Kamphuis, W. Kuis, W. de Jager, G. Teklenburg, M. Massa, G. Gordon, M. Boerhof, G.T. Rijkers, C.S. Uiterwaal, H.G. Otten, A. Sette, S. Albani, and B.J. Prakken, Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 juvenile idiopathic arthritis, Lancet, 366: 50-56, 2005.
144. G. Teklenburg and S. Albani, The role of immune tolerance in preventing and treating arthritis, Curr. Rheum. Rep., 6: 434-441, 2004.
145. B.J. Prakken, D.A. Carson, and S. Albani, T cell repertoire formation and molecular mimicry in rheumatoid arthritis, Curr. Directions Autoimmun., 3: 51-63, 2001.
146. J.A. Smith, J.Y. Tso, M.L. Clark, M.S. Cole, and J.A. Bluestone, Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy, J. Exp. Med., 185: 1413-1422, 1997.
147. Q. Tang, K.J. Henriksen, M. Bi, E.B. Finger, G. Szot, J. Ye, E.L. Masteller, H. McDevitt, M. Bonyhadi, and J.A. Bluestone, In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes, J. Exp. Med., 199: 1455-1465, 2004.
148. K.C. Herold, et al., A single corse of anti-CD3 monoclonal antibody hOKT3gamma (AlaAla) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes, Diabetes, 54: 1763-1769, 2005.
149. B. Bisikirska, J. Colgan, J. Luban, J.A. Bluestone, and K.C. Herold, In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes, J. Exp. Med., 199: 1455-1465, 2005.
150. E.S. Woodle, D. Xu, R.A. Zivin, J. Auger, J. Charette, R. O'Laughlin, D. Peace, L.K. Jollife, T. Haverty, J.A. Bluestone, and J.R. Thistlethwaite, Jr., Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gammal(AlaAla) in the treatment of acute renal allograft rejection, Transplantation, 68: 608-616, 1999.
151. B.J. Hering, R. Kandaswamy, J.V. Harmon, J.D. Ansite, S.M. Clemmings, T. Sakai, S. Paraskevas, P.M. Eckman, J. Sageshima, M. Nakano, T. Sawada, I. Matsumoto, H.J. Zhang, D.E. Sutherland, and J.A. Bluestone, Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody, Am. J. Transplant., 4: 295-298, 2004.
152. T.O. Utset, J.A. Auger, D. Peace, R.A. Zivin, D. Xu, L. Jolliffe, M.L. Alegre, J.A. Bluestone, and M.R. Clark, Modified anti-CD3 therapy in psoriatic arthritis: A phase I/II clinical trial, J. Rheumatol., 29: 1907-1913, 2002.
153. M.A. Cheever and W. Chen, Therapy with cultured T cells: Principles revisited, Immunol. Rev., 157: 177-194, 1997.
154. A. Lanzavecchia, Identifying strategy for immune intervention, Science, 260: 937-944, 1993.
155. J. Zhang, R. Medaer, P. Stinissen, D. Hafler, and J. Raus, MHC-restricted depletion of human basic protein-reactive T cells by T cell vaccination, Science, 261: 1451-1454, 1993.
156. V. Kumar, R. Tabibiazar, H.M. Geysen, and E. Sercaz, Immunodominant framework region 3 peptide from TcR beta 8.2 chain controls murine experimental immune encephalomyelitis, J. Immunol., 154: 1941-1950, 1995.
157. V. Kumar, Homeostatic control of immunity by TcR peptide-specific T regs, J. Clin. Invest., 114: 1222-1226, 2004.
158. P. Hutchings, N.M. Parish, H. Waldmann, and A. Cooke, The use of a non-depleting anti-CD4 monoclonal antibody to re-establish tolerance to beta cells in NOD mice, Eur. J. Immunol., 22: 1913-1918, 1992.
159. S.X. Qin, M. Wise, S.P. Cobbold, L. Leong, Y.C. Kong, J.R. Parnes, and H. Waldmann, Induction of tolerance in peripheral T cells with monoclonal antibodies, Eur. J. Immunol., 20: 2737-2745, 1990.
160. A. O'Garra, P.L. Vieira, P. Vieira, and A.E. Goldfeld, IL-10 producing and natural occurring CD4+ Tregs: Limiting collateral damage, J. Clin. Invest., 114: 1372-1378, 2004.
161. P. Tan, A.C. Hansen, J. Melrose, M. Brunvand, J. Bradshaw, J.A. Ledbetter, and P.S. Linsley, Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1, J. Exp. Med., 177: 165-173, 1993.
162. E. Boden, Q. Tang, H. Bour-Jordan, and J.A. Bluestone, The role of CD28 and CTLA4 in the function and homeostasis of CD4+ CD25+ regulatory T cells, Novartis Found. Symp., 252: 55-63, 2003.
163. L. Guo, M. Fujino, H. Kimura, N. Funeshima, Y. Kitazawa, Y. Harihara, K. Tezuka, M. Makuuki, S. Suzuki, and S.K. Li, Simultaneous blockade of co-stimulatory signals, CD28 and ICOS, induced a stable tolerance in rat heart transplantation, Transplant Immunol., 12: 41-48, 2003.